Erythrocyte-incorporated 6-mercaptopurine metabolite levels are not affected by recent drug administration during maintenance therapy for childhood acute lymphoblastic leukemia

Erythrocyte-incorporated 6-mercaptopurine metabolite levels are not affected by recent drug administration during maintenance therapy for childhood acute lymphoblastic leukemia

Background: Childhood acute lymphoblastic leukemia (ALL) maintenance therapy with oral 6-mercaptopurine (6-MP) and methotrexate prevents leukemic relapse by acting against residual lymphoblasts. Non-adherence to oral maintenance therapy significantly increases ALL relapse risk. The levels of intrace...

Full description

Bibliographic Details
Main Authors: Lauryna Aukstikalne, Ignas Klejus, Maria Thastrup, Tadas Zvirblis, Kjeld Schmiegelow, Goda Elizabeta Vaitkeviciene, Linea Natalie Toksvang
Format: Article
Language:English
Published: Elsevier 2023-12-01
Series:EJC Paediatric Oncology
Subjects:
Leukemia
Acute
Lymphoblastic
Maintenance therapy
6-mercaptopurine
Relapse
Online Access:http://www.sciencedirect.com/science/article/pii/S2772610X23000260

Internet

http://www.sciencedirect.com/science/article/pii/S2772610X23000260

Similar Items